[1] Jerome T, Alexa SG, Valerie B, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia[J].Blood,2009(114): 1618-1627. [2] Popovsky MA. Transfusion and lung injury[J]. Transfus Clin Bjol, 2001, 8(3): 272-277. [3] Kamisawa T,Matsukawa M,Amemiya K,et al. Pancreatitis associated with pancraticobiliary maljunction system[J]. Heptogastroenterology,2005, 52(61):223-229. [4] Fielhaber JA, Carroll SF, Dydensborg AB, et al.Inhibition of mammalian target of rapamycin augments lipopolysaccharide-induced lung injury and apoptosis[J]. J Immunol, 2012,188(9): 4535-4542. [5] Tahk S, Liu B, Chernishof V, et al. Control of specificity and magnitude of NF-κB and STAT1-mediated gene activation through PIASy and PIAS1 cooperation[J]. Proceedings of the National Academy of Sciences, 2007, 104(28): 11643-11648. [6] http://www.ncbi.nlm.nih.gov/genbank [7] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method[J]. Methods, 2001,25(4):402-408. [8] Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors[J]. Blood, 2012,119(7):1757-1767. [9] Squires JE. Risks of transfusion[J]. South Med J, 2011, 104(11): 762-769. [10] Kelher MR, Masuno T, Moore EE, et al. Plasma from stored packed red blood cells and MHC class I antibodies cause acute lung injury in a two-event in vivo rat model[J]. Blood, 2009, 113(9): 2079-2087. [11] Schmidt J Rattner DW Lewandrowski K,et al. A better model of acute pancreatitis for evaluation therapy[J]. Ann Surg,1992,215(1): 44-56. [12] Laplante M, Sabatini DM. mTOR signaling in growth control and disease[J]. Cell, 2012, 149(2): 274-293. [13] Lorne E, Zhao X, Zmijewski J W, et al. Participation of Mammalian Target of Rapamycin Complex 1 in Toll-Like Receptor 2-and 4-Induced Neutrophil Activation and Acute Lung Injury[J].American journal of respiratory cell and molecular biology, 2009, 41(2): 237-245. |